These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16270653)

  • 1. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy.
    Utikal J; Peitsch WK; Booken D; Velten F; Dempfle CE; Goerdt S; Bayerl C
    Thromb Haemost; 2005 Oct; 94(4):895-6. PubMed ID: 16270653
    [No Abstract]   [Full Text] [Related]  

  • 2. Intolerance of fondaparinux in a patient allergic to heparins.
    Hirsch K; Ludwig RJ; Lindhoff-Last E; Kaufmann R; Boehncke WH
    Contact Dermatitis; 2004 Jun; 50(6):383-4. PubMed ID: 15274739
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
    Colagiovanni A; Rizzi A; Buonomo A; De Pasquale T; Pecora V; Sabato V; Aruanno A; Pascolini L; Nucera E; Schiavino D
    Contact Dermatitis; 2010 Aug; 63(2):107-8. PubMed ID: 20629676
    [No Abstract]   [Full Text] [Related]  

  • 5. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
    Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
    Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux.
    Koch P
    Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux.
    Maetzke J; Hinrichs R; Schneider LA; Scharffetter-Kochanek K
    Allergy; 2005 Mar; 60(3):413-5. PubMed ID: 15679737
    [No Abstract]   [Full Text] [Related]  

  • 8. A Case of Heparin Allergy With Good Tolerability to Fondaparinux During Pregnancy.
    Buonomo A; Nucera E; De Carolis S; De Stefano V; Pascolini L; Di Pasquo E; Betti S ; Schiavino D
    J Investig Allergol Clin Immunol; 2015; 25(3):229-31. PubMed ID: 26182695
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-immediate heparin and heparinoid cutaneous allergic reactions: a role for fondaparinux.
    Tan E; Thompson G; Ekstrom C; Lucas M
    Intern Med J; 2018 Jan; 48(1):73-77. PubMed ID: 29314514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study.
    Gaigl Z; Pfeuffer P; Raith P; Bröcker EB; Trautmann A
    Br J Haematol; 2005 Feb; 128(3):389-92. PubMed ID: 15667543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed hypersensitivity skin reaction to enoxaparin.
    Méndez J; de la Fuente R; Stolle R; Vega JM; Sanchís ME; Armentia A; Sánchez P; Fernández A
    Allergy; 1996 Nov; 51(11):853-4. PubMed ID: 8947349
    [No Abstract]   [Full Text] [Related]  

  • 12. Eczema-like plaques to enoxaparin.
    Valdés F; Vidal C; Fernández-Redondo V; Peteiro C; Toribio J
    Allergy; 1998 Jun; 53(6):625-6. PubMed ID: 9689351
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin.
    Schindewolf M; Ludwig RJ; Wolter M; Himsel A; Zgouras D; Kaufmann R; Boehncke WH; Lindhoff-Last E
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):378-80. PubMed ID: 18269612
    [No Abstract]   [Full Text] [Related]  

  • 15. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux.
    Hohenstein E; Tsakiris D; Bircher AJ
    Contact Dermatitis; 2004 Sep; 51(3):149-51. PubMed ID: 15479206
    [No Abstract]   [Full Text] [Related]  

  • 16. [Delayed-type hypersensitivity to heparin: diagnosis and therapeutic management].
    Nosbaum A; Pralong P; Rozieres A; Dargaud Y; Nicolas JF; Bérard F
    Ann Dermatol Venereol; 2012 May; 139(5):363-8. PubMed ID: 22578340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy.
    Maetzke J; Hinrichs R; Staib G; Scharffetter-Kochanek K
    Allergy; 2004 Feb; 59(2):237-8. PubMed ID: 14763948
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerance to the synthetic pentasaccharide fondaparinux in heparin sensitization.
    Sacher C; Hunzelmann N
    Allergy; 2003 Dec; 58(12):1318-9. PubMed ID: 14616114
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.